Biopharmaceutical Contract Manufacturing Market
Market Insights on Biopharmaceutical Contract Manufacturing covering sales outlook, demand forecast & up-to-date key trends
Biopharmaceutical Contract Manufacturing Market By Platform , Product, Application & Region - Forecast to 2022 - 2029
Biopharmaceutical Contract Manufacturing Market Outlook (2022-2029)
A Summary of Biopharmaceutical Contract Manufacturing Market Developments:
[221 Pages Report] Global demand for the biopharmaceutical contract manufacturing market is expected to register a CAGR of 10.5% by garnering a market value of US$ 18.7 Billion by 2029. The growth of the market can be attributed to
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 8.4 Bn |
|
Market Value 2022 |
US$ 9.3 Bn |
|
Market Value 2029 |
US$ 18.7 Bn |
|
CAGR 2022-2029 |
10.5% |
|
Market Share of Top 5 Countries |
59.5% |
- Increase in funding for research and development activities by healthcare sector to develop pharmaceutical products is creating lucrative opportunities for biopharmaceutical contract manufacturing market.
- Technological advancements in biological research are rapidly changing the biopharmaceutical contract manufacturing. This, in turn, is helping the market to grow.
- The lack of availability of production capacities across the globe is spurring the demand for biopharmaceutical contract manufacturing market.
During the COVID-19 pandemic from 2020-2022, the research and development sector was redesigned on a large scale. The urgent need for research and production of vaccines on a large scale contributed largely to the biopharmaceutical contract manufacturing market. With technological integration being at the forefront of research, the development of biopharmaceutical contract management market has increased.
The expansion of the biopharmaceutical industry owing to the demand of vaccines. Moreover, certain companies are facing production issues along with lack of expertise and sophisticated equipment. This, in turn, is increasing lucrative opportunities for biopharmaceutical manufacturing contract. In addition, the availability of external funding have resulted in the growth in a number of early-stage bio/pharma companies.
Let us know your requirement to get
100% FREE customization
Low Manufacturing Costs and Increasing Investments Favoring Biopharmaceutical Contract Manufacturing Market Growth in Asia Pacific
China is the largest contributor to biopharmaceutical contract manufacturing owing to the increasing investment in the sector. Moreover, the country is planning to capitalize on the growth of the biopharmaceutical industry. On the other hand, China is planning to collaborate with local and international organizations to expand its biopharmaceutical capacity. Furthermore, the established presence of pharma and biopharma companies is helping the market to grow.
Expansion in the offerings of the services along with the increasing focus on outsourcing processes by multiple biopharmaceutical industries is positively influencing the growth of biopharmaceutical contract manufacturing market. In addition, increase in investments in research and development area is creating opportunities for biopharmaceutical manufacturing contract market.
Furthermore, low manufacturing and operating costs in countries such as China India and Korea is making the growth of the market favorable. The development of the biopharmaceutical industry in Korea is expected to boost revenue generation from the Asia Pacific region.
Opportunities in the Biopharmaceutical Contract Manufacturing Market
Biopharmaceutical development consists of intensive investigation that uses various sources and species for product innovation. The objective of these investigations is to not only enhance productivity but also efficiency of biopharmaceutical manufacturing. Owing to this, mammalian-based biomanufacturing is creating lucrative opportunities for biopharmaceutical contract manufacturing market.
In addition, higher efficiency and less time-consuming nature of mammalian-based is gaining traction for the same. For instance, mammalian based cell culture such as recombinant monoclonal antibodies and Chinese Hamster Ovary cells (CHO) are widely being used for the production of biopharmaceuticals in large quantities In comparison to other platforms.
Leading contract manufacturing organizations are focusing on geographical expansion to gain high revenue & expand their sales footprint in emerging countries by acquisition of local market players. Strategic divestitures, collaborations, exclusive partnership agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.
The continuous growth in life science research segment, increased R&D funding and development of various pharmaceutical products in various countries across the globe has added significantly to the growth of biopharmaceutical contract manufacturing market.
The biopharmaceutical contract manufacturing market holds less than 1% of the global contract manufacturing market in 2021 which is valued at nearly 2300 Bn.
In biopharmaceutical contract manufacturing market, a large number of local players as well as established players are significantly showing interest in either conducting biologic drug based research and development or performing bio-manufacturing processes in different countries, besides marketing their own products there.
Furthermore, the production of vaccines, biosimilars, recombinant proteins and monoclonal antibodies etc., using various technologies has been undertaken by utilizing outsourcing strategy by various manufacturers.
On the other hand, the virtual biotechnology companies with early clinical products uses outsourcing strategy wherein they collaborate with CMOs with smaller facilities for clinical supply at initial stage. Later on, they switch the production to another CMO who is capable of doing production in large batches and is enough experienced in moving products through the clinical phases. For early-stage projects, big biopharmaceuticals companies approach small CMOs. For commercial products, companies tie up with top tier CMO with expertise in vials and who have experience with the FDA.
To meet customer needs, biopharmaceutical companies are entering into various contract manufacturing agreements with contract manufacturing organization (CMO) and Contract manufacturing and development organization (CDMO).
Considering this, it is estimated for the biopharmaceutical contract manufacturing market to grow significantly over the forecast duration.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
10.62% |
|
H1, 2022 Projected |
10.62% |
|
H1, 2022 Outlook |
10.62% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 10 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 24 ↓ |
According to FMI, the biopharmaceuticals contract manufacturing market will drop in H1-2022(O) when compared with H1-2021 by 24 basis point share (BPS). Some of the main reasons for the deterioration in BPS are greater production time, higher costs, risk of intellectual property exchange, and lack of communication channels between biopharma companies and contract manufacturing organizations.
The growth rates and development possibilities of the global biopharmaceuticals contract manufacturing market are compared by FMI. The market is influenced by quality control, drug stability studies, regulations, and the impact of macro and industrial variables. This, in turn, is expected to affect the market growth rate in the H1-2022 outlook period to show a dip by nearly 10 BPS when compared with H1-2022 projected period.
While the biopharmaceutical industry has made significant progress, the contract manufacturing and development organisation (CDMO), which develops and manufactures drug substances for biopharmaceutical companies, has grown at the same time, demonstrating a pharmaceutical industry ecosystem that is a horizontal division model of drug research by pharmaceutical and biotech organisations, along with drug manufacture by CDMOs, and is a key driving factor in this sector.
Reduction in sourcing and production costs conversely provide a lucrative growth impact on the biopharmaceuticals contract manufacturing market.
Sales Analysis of Biopharmaceutical Contract Manufacturing from 2012 to 2021 Vs Market Outlook for 2022 to 2029
Sales of biopharmaceutical contract manufacturing market grew at a CAGR of 9.5% between 2012 and 2021.
Biopharmaceuticals contract manufacturing firms play an important role in commercial manufacturing as well as late clinical phase of biologics production. Big pharma companies have limited capacity for biologics production. This incapability leads towards outsourcing of biologics production, which is leading to the growth in the biopharmaceutical contract manufacturing market.
The growth of the biopharmaceutical contact manufacturing industry globally is also driven by strong biologics pipeline that fuel the demand for these CMOs (Contact Manufacturing Organizations). A large number of biotech patents are applied every year and this tends to be growing at 23% annually. Nearly 1500 biomolecules are currently under clinical trials, targeting more than 100 types of diseases, the biologics have shown two times higher success rate as compared to small-molecule products. The current biologics-development pipeline thus, supports an outlook of continued healthy growth.
The market is expected to expand at a considerable growth rate over the next seven years at a CAGR of close to 10.5% from 2022 to 2029.
A unified Market Research Subscription Platform, built for today's disparate research needs.
What are the Key Opportunities Biopharmaceutical Contract Manufacturing?
Key players acting in this market are opting for inorganic growth strategies to boost their earnings and grow market share by way of providing integrated solutions to customers. While few companies are undertaking merger and acquisitions to grow their consumer base, others are involved in aggressive expansion of their product/services/capabilities through strategic alliances. Furthermore, integration strategy of acquiring manufacturing facilities from large pharmaceutical companies is being adopted as another key strategy.
For instance, In July 2020, Fujifilm acquired the Biogen’s large-scale bio-manufacturing facility for US$ 890 million. Similarly, In July 2021, AbbVie Company acquired Allergen. This acquisition helped AbbVie expand its global operations in order to supply end-to-end drug substance and product to manufacturing partners of AbbVie. The contract manufacturing services offers topical creams and ointments, biologics fill-finish, sterile ophthalmic ointments and custom API.
Additionally, many organizations are focusing on reducing the overall operational cost associated with R&D and commercialization of a drug, by looking out for outsourcing options to CMOs. Outsourcing at a later stage of clinical development through identification and appointment of a strategic partner could improve efficiencies all along the value chain.
The CDMO & CMO business model is emerging as a key differentiating strategy which is transforming the pharmaceutical ecosystem, disrupting drug development and manufacturing technologies and providing major growth opportunities in high potency and biopharmaceuticals manufacturing. Thus, providing for long-term profitability of CMOs at the global level.
These developments are thus, set to provide the biopharmaceutical contract manufacturing market with profitable prospects over the forecast period.
What are the Factors Restraining Demand for Biopharmaceutical Contract Manufacturing?
Biopharmaceuticals manufacturing capacity is one of the important factors in the growth of the market. Manufacturing of drugs in bulk volumes requires facilities to have large scale plants with huge capacity and big funding. Globally, biopharma companies have spent billions in just the past few years on new plants and equipment. Much of that has been in tax havens, like Ireland and Singapore, and in emerging markets. About a quarter of the projects have been in the US.
Additionally, development of a new plants takes nearly 4 years to design, build and qualify, while costing anywhere between US$ 250 million to US$ 2 billion, which is too high as compared to small scale pants and industries. Also, with availability of limited yet traditional facilities, it is not enough and also too old to develop any modern drugs. Thus, limited CMO facility together with the need for huge capital investment poses a major restraining factor for the growth of this market.
Another major factor impacting this market is the changing regulatory dynamics around the globe. Global regulatory policies, tightening regime of inspection and supply chain security related issues across countries impacts largely on the cost of final products and ultimately makes the market entry for new players a costly decision due to financial constraints along with the aforementioned factors.
The increasing complexity of biopharmaceuticals operations and the biopharmaceuticals supply chain has already stretched the current production programs across industries. Many players are thus, constantly failing to deliver to the market. All these factors are expected to hinder the growth of the biopharmaceutical contract manufacturing market over the forecast duration globally.
Country-wise Insights
What Makes the U.S. the Largest Market for Biopharmaceutical Contract Manufacturing?
The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period. The growth of this market is driven by the high corporate venture capital investments which are helping to advance biotechnology R&D, strong biologics pipeline fuelling the demand for the CMOs and establishment of key manufacturers & research institutes with dedicated programs for the contract manufacturing organizations.
Why is Germany Considered a Lucrative Market for Biopharmaceutical Contract Manufacturing?
Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option. Thus, more research and clinical trials in biopharmaceuticals to reduce the cost and focus on outsourcing of most research activities is raising the demand for biopharmaceutical contract manufacturing market in Germany.
What Makes China an Emerging Market for Biopharmaceutical Contract Manufacturing?
China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth, including seeking the opportunities to collaborate/partner with the local organizations which is helping this region to emerge and grow over the forecast period.
What is the Outlook for India Regarding Biopharmaceutical Contract Manufacturing?
In 2021, India held a 30.4% share in the global Biopharmaceutical Contract Manufacturing market and is projected to expand at a CAGR of 11.9% from 2022 to 2029. India projects a significant growth in the global biopharmaceutical contract manufacturing market owing to increase in the investments in research and development area, expansion in the offerings of the services and increase in the outsourcing processes by different biopharmaceutical industries.
Category-wise Insights
Which Biopharmaceutical Contract Manufacturing Platform is Driving Market Growth?
Mammalian-based segment hold the largest market share of 72.8% in 2021 and is projected to grow over the forecast period, with CAGR of about 12.3% due to higher efficiency and less time-consuming effort. Mammalian based cell culture such as Chinese Hamster Ovary cells (CHO) and recombinant monoclonal antibodies have been used for the production of biopharmaceuticals in large quantities as compared to other platforms.
Which Biopharmaceutical Contract Manufacturing Product is Driving Market Growth?
Monoclonal Antibodies products project a lucrative growth at a CAGR of 11.6% till the end of the forecast period, with a market share of around 50.0% in 2021. Increasing prevalence of metabolic diseases and cancer is helping to increase the revenue share of the recombinant protein and insulin segment of the monoclonal antibodies due to increased usage in the research field.
Why is Commercial application being Widely Adopted Application in the Biopharmaceutical Contract Manufacturing Market?
Commercial application enjoys a revenue share of 78.7% in the global biopharmaceutical contract manufacturing market in 2021. Commercial segment revenue share is expected to increase further over the forecast duration with a growth rate of 10.9% due to the increasing biologic drugs demand and large scale up facility of contract manufacturing organizations.
Which Therapeutic Area is Largely of Focus in the Biopharmaceutical Contract Manufacturing Market?
Oncology holds a revenue share of 20.9% in 2021 and are projected to grow over the forecast period with CAGR of 13.6%. The segment holds the largest revenue share due to the increasing incidences and prevalence of the targeted diseases in the oncology segment all over the Globe. Additionally, large number of clinical research activities to develop new therapeutic options and involvement of large number of manufacturers introducing novel product lines in this field further adds to the growth of this market.
Competitive Landscape
Leading contract manufacturing organizations are focusing on geographical expansion to gain high revenue & expand their sales footprint in emerging countries by acquisition of local market players.
Strategic divestitures, collaborations, exclusive partnership agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.
- In 2021, Lonza Group Ag, disclosed its highest sale after selling Lonza Speciality Ingredients to Bain Capital Private Equity for $4.4B.
- In November 2021, Abzena limited, a partner research organization for integrated discovery of cGMP and a manufacturer of biopharmaceuticals solutions collaborated with BiVictriX Therapeutics plc, a biotechnology company to manufacture the BiVictriX’s antibody-drug conjugates (ADC).
- In September 2021 Novasep Company did an exclusive partnership with PharmaZell. The partnership is focussed to develop, manufacture and expand, complex small molecules and ADCs at a global scale.
Similarly, recent developments related to companies of biopharmaceuticals contract manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as per Biopharmaceutical Contract Manufacturing Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2022-2029 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan and Middle East & Africa |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, North Africa, GCC Countries, Turkey, and South Africa |
|
Key Market Segments Covered |
Platform, Product, Application, Therapeutic area, and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- Middle East and Africa (MEA)
Frequently Asked Questions
How much is the Biopharmaceutical Contract Manufacturing market currently worth?
The global biopharmaceutical contract manufacturing market is worth US$ 9.28 Bn in 2021 and is estimated to grow 2 times over the forecast duration.
What is the sales forecast for Biopharmaceutical Contract Manufacturing through 2029?
The biopharmaceutical contract manufacturing market is expected to reach US$ 18.65 Bn by the end of 2029, with sales revenue expected to register 10.5% CAGR.
What are the key trends shaping the Biopharmaceutical Contract Manufacturing industry?
Growing technical advancements, strategic research collaborations, acquisitions & expansion by outsourcing of biopharmaceuticals manufacturing and accelerating product adoption rate are some of the key trends being witnessed in this marketplace.
Which are the top 5 countries driving demand for Biopharmaceutical Contract Manufacturing?
The U.S., China, India, Japan, Germany are expected to drive demand in biopharmaceutical contract manufacturing market.
What is the North America market outlook for Biopharmaceutical Contract Manufacturing?
North America is one of the key markets for biopharmaceutical contract manufacturing, with the U.S. expected to account for nearly 91.0% of the North American market during the forecast period.
At what percentage is the demand for Biopharmaceutical Contract Manufacturing expected to register growth in Eastern Europe?
Demand for biopharmaceutical contract manufacturing in Eastern Europe is expected to register growth of 10% over the next seven years.
Which are the key exporters of Biopharmaceutical Contract Manufacturing market?
Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd. , ProBioGen AG , Pfizer Centre Source Ltd (Pfizer Inc.), Novasep , Biomeva GmbH, Kbi Biopharma Inc, Rentschler Biotechnologie GmbH and Ajinomoto Althea Inc., (Ajinomoto Co., Inc.) are the key
Table of Content
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. Analysis and Recommendations 2. Market Introduction 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 3.3. Regulatory Overview 4. Global Market Analysis 2012-2021 and Opportunity Assessment, 2022-2029 4.1. Historical Market Value (US$ Mn) Analysis, 2012-2021 4.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Incremental Opportunity Analysis 4.2.3. Market Value Comparison 5. Global Market Analysis 2012-2021 and Forecast 2022-2029, by Platform 5.1. Introduction / Key Findings 5.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2021 5.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Platform, 2022-2029 5.3.1. Mammalian 5.3.2. Microbial 5.4. Market Attractiveness Analysis By Platform 6. Global Market Analysis 2012-2021 and Forecast 2022-2029, by Product 6.1. Introduction / Key Findings 6.2. Historical Market Size (US$ Mn) Analysis By Product, 2012–2021 6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2029 6.3.1. Growth Factors 6.3.2. Interferon’s 6.3.3. Monoclonal Antibodies 6.3.4. Recombinant Hormones 6.3.5. Vaccines 6.3.6. Insulin 6.3.7. Others 6.4. Market Attractiveness Analysis By Product 7. Global Market Analysis 2012-2021 and Forecast 2022-2029, by Application 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2021 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2029 7.3.1. Clinical 7.3.2. Commercial 7.4. Market Attractiveness Analysis By Application 8. Global Market Analysis 2012-2021 and Forecast 2022-2029, by Therapeutic Area 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2022-2029 8.3.1. Autoimmune Diseases 8.3.2. Oncology 8.3.3. Metabolic Diseases 8.3.4. Ophthalmology 8.3.5. Cardiovascular Diseases 8.3.6. Infectious Diseases 8.3.7. Neurology 8.3.8. Respiratory Disorders 8.3.9. Others 8.4. Market Attractiveness Analysis By Therapeutic Area 9. Global Market Analysis 2012-2021 and Forecast 2022-2029, by Region 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021 9.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022-2029 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. APEJ 9.3.6. Japan 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2012-2021 and Forecast 2022-2029 10.1. Introduction 10.2. Regional Market Dynamics 10.2.1. Drivers 10.2.2. Restraints 10.2.3. Trends 10.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 10.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 10.4.1. By Country 10.4.1.1. U.S. 10.4.1.2. Canada 10.4.2. By Platform 10.4.3. By Product 10.4.4. By Application 10.4.5. By Therapeutic Area 10.5. Market Attractiveness Analysis 10.5.1. By Country 10.5.2. By Platform 10.5.3. By Product 10.5.4. By Application 10.5.5. By Therapeutic Area 10.6. Key Market Participants - Intensity Mapping 11. Latin America Market Analysis 2012-2021 and Forecast 2022-2029 11.1. Introduction 11.2. Regional Market Dynamics 11.2.1. Drivers 11.2.2. Restraints 11.2.3. Trends 11.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 11.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 11.4.1. By Country 11.4.1.1. Mexico 11.4.1.2. Brazil 11.4.1.3. Rest of Latin America 11.4.2. By Platform 11.4.3. By Product 11.4.4. By Application 11.4.5. By Therapeutic Area 11.5. Market Attractiveness Analysis 11.5.1. By Platform 11.5.2. By Product 11.5.3. By Application 11.5.4. By Therapeutic Area 11.6. Key Market Participants - Intensity Mapping 12. Western Europe Market Analysis 2012-2021 and Forecast 2022-2029 12.1. Introduction 12.2. Regional Market Dynamics 12.2.1. Drivers 12.2.2. Restraints 12.2.3. Trends 12.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 12.4.1. By Country 12.4.1.1. U.K. 12.4.1.2. Germany 12.4.1.3. France 12.4.1.4. Italy 12.4.1.5. Spain 12.4.1.6. BENELUX 12.4.1.7. Nordic 12.4.1.8. Rest of Western Europe 12.4.2. By Platform 12.4.3. By Product 12.4.4. By Application 12.4.5. By Therapeutic Area 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Platform 12.5.3. By Product 12.5.4. By Application 12.5.5. By Therapeutic Area 12.6. Key Market Participants - Intensity Mapping 13. Eastern Europe Market Analysis 2012-2021 and Forecast 2022-2029 13.1. Introduction 13.2. Regional Market Dynamics 13.2.1. Drivers 13.2.2. Restraints 13.2.3. Trends 13.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 13.4.1. By Country 13.4.1.1. Russia 13.4.1.2. Poland 13.4.1.3. Rest of Eastern Europe 13.4.2. By Platform 13.4.3. By Product 13.4.4. By Application 13.4.5. By Therapeutic Area 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Platform 13.5.3. By Product 13.5.4. By Application 13.5.5. By Therapeutic Area 13.6. Key Market Participants - Intensity Mapping 14. APEJ Market Analysis 2012-2021 and Forecast 2022-2029 14.1. Introduction 14.2. Regional Market Dynamics 14.2.1. Drivers 14.2.2. Restraints 14.2.3. Trends 14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 14.4.1. By Country 14.4.1.1. China 14.4.1.2. India 14.4.1.3. Australia & New Zealand 14.4.1.4. ASEAN 14.4.1.5. South Korea 14.4.1.6. Rest of APEJ 14.4.2. By Platform 14.4.3. By Product 14.4.4. By Application 14.4.5. By Therapeutic Area 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Platform 14.5.3. By Product 14.5.4. By Application 14.5.5. By Therapeutic Area 14.6. Key Market Participants - Intensity Mapping 15. Japan Market Analysis 2012-2021 and Forecast 2022-2029 15.1. Introduction 15.2. Regional Market Dynamics 15.2.1. Drivers 15.2.2. Restraints 15.2.3. Trends 15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 15.4.1. By Platform 15.4.2. By Product 15.4.3. By Application 15.4.4. By Therapeutic Area 15.5. Market Attractiveness Analysis 15.5.1. By Platform 15.5.2. By Product 15.5.3. By Application 15.5.4. By Therapeutic Area 15.6. Key Market Participants - Intensity Mapping 16. Middle East and Africa Market Analysis 2012-2021 and Forecast 2022-2029 16.1. Introduction 16.2. Regional Market Dynamics 16.2.1. Drivers 16.2.2. Restraints 16.2.3. Trends 16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. Turkey 16.4.1.3. North Africa 16.4.1.4. South Africa 16.4.1.5. Rest of Middle East & Africa 16.4.2. By Platform 16.4.3. By Product 16.4.4. By Application 16.4.5. By Therapeutic Area 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Platform 16.5.3. By Product 16.5.4. By Application 16.5.5. By Therapeutic Area 16.6. Key Market Participants - Intensity Mapping 17. Competition Landscape 17.1. Competition Dashboard 17.2. Company Deep Dive 17.2.1. Catalent Inc. 17.2.1.1. Overview 17.2.1.2. Product Overview 17.2.1.3. Key Financials 17.2.1.4. Key Developments 17.2.1.5. SWOT Analysis 17.2.1.6. Strategic Overview 17.2.2. Lonza Group Ag 17.2.2.1. Overview 17.2.2.2. Product Overview 17.2.2.3. Key Financials 17.2.2.4. Key Developments 17.2.2.5. SWOT Analysis 17.2.2.6. Strategic Overview 17.2.3. Patheon N.V. (Thermo Fisher Scientific Inc.) 17.2.3.1. Overview 17.2.3.2. Product Overview 17.2.3.3. Key Financials 17.2.3.4. Key Developments 17.2.3.5. SWOT Analysis 17.2.3.6. Strategic Overview 17.2.4. Abzena Plc. 17.2.4.1. Overview 17.2.4.2. Product Overview 17.2.4.3. Key Financials 17.2.4.4. Key Developments 17.2.4.5. SWOT Analysis 17.2.4.6. Strategic Overview 17.2.5. Sandoz International GmbH (Novartis AG) 17.2.5.1. Overview 17.2.5.2. Product Overview 17.2.5.3. Key Financials 17.2.5.4. Key Developments 17.2.5.5. SWOT Analysis 17.2.5.6. Strategic Overview 17.2.6. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings) 17.2.6.1. Overview 17.2.6.2. Product Overview 17.2.6.3. Key Financials 17.2.6.4. Key Developments 17.2.6.5. SWOT Analysis 17.2.6.6. Strategic Overview 17.2.7. Baxter Pharmaceutical Solutions LLC (Baxter Inc.) 17.2.7.1. Overview 17.2.7.2. Product Overview 17.2.7.3. Key Financials 17.2.7.4. Key Developments 17.2.7.5. SWOT Analysis 17.2.7.6. Strategic Overview 17.2.8. AbbVie Contract Manufacturing (AbbVie Inc.) 17.2.8.1. Overview 17.2.8.2. Product Overview 17.2.8.3. Key Financials 17.2.8.4. Key Developments 17.2.8.5. SWOT Analysis 17.2.8.6. Strategic Overview 17.2.9. Samsung Biologics Co. Ltd. 17.2.9.1. Overview 17.2.9.2. Product Overview 17.2.9.3. Key Financials 17.2.9.4. Key Developments 17.2.9.5. SWOT Analysis 17.2.9.6. Strategic Overview 17.2.10. ProBioGen AG 17.2.10.1. Overview 17.2.10.2. Product Overview 17.2.10.3. Key Financials 17.2.10.4. Key Developments 17.2.10.5. SWOT Analysis 17.2.10.6. Strategic Overview 17.2.11. Pfizer Centre Source Ltd (Pfizer Inc.) 17.2.11.1. Overview 17.2.11.2. Product Overview 17.2.11.3. Key Financials 17.2.11.4. Key Developments 17.2.11.5. SWOT Analysis 17.2.11.6. Strategic Overview 17.2.12. Novasep 17.2.12.1. Overview 17.2.12.2. Product Overview 17.2.12.3. Key Financials 17.2.12.4. Key Developments 17.2.12.5. SWOT Analysis 17.2.12.6. Strategic Overview 17.2.13. Biomeva GmbH 17.2.13.1. Overview 17.2.13.2. Product Overview 17.2.13.3. Key Financials 17.2.13.4. Key Developments 17.2.13.5. SWOT Analysis 17.2.13.6. Strategic Overview 17.2.14. Kbi Biopharma Inc 17.2.14.1. Overview 17.2.14.2. Product Overview 17.2.14.3. Key Financials 17.2.14.4. Key Developments 17.2.14.5. SWOT Analysis 17.2.14.6. Strategic Overview 17.2.15. Rentschler Biotechnologie GmbH 17.2.15.1. Overview 17.2.15.2. Product Overview 17.2.15.3. Key Financials 17.2.15.4. Key Developments 17.2.15.5. SWOT Analysis 17.2.15.6. Strategic Overview 17.2.16. Ajinomoto Althea Inc. (Ajinomoto Co., Inc.) 17.2.16.1. Overview 17.2.16.2. Product Overview 17.2.16.3. Key Financials 17.2.16.4. Key Developments 17.2.16.5. SWOT Analysis 17.2.16.6. Strategic Overview 18. Assumption and Acronyms Used 19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Market Value (US$ Mn) Growth Comparison Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Product Table 04: Global Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Application Table 05: Global Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Therapeutic Area Table 06: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Region Table 07: North America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 08: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 09: North America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 10: North America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 11: North America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country Table 12: Latin America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 13: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 14: Latin America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 15: Latin America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 16: Latin America Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country Table 17: Western Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 18: Western Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 19: Western Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 20: Western Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 21: Western Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country Table 22: Eastern Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 23: Eastern Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 24: Eastern Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 25: Eastern Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 26: Eastern Europe Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country Table 27: APEJ Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 28: APEJ Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 29: APEJ Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 30: APEJ Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 31: APEJ Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country Table 32: Japan Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 33: Japan Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 34: Japan Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 35: Japan Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 36: Middle East & Africa Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application Table 37: Middle East & Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type Table 38: Middle East & Africa Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product Table 39: Middle East & Africa Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area Table 40: Middle East & Africa Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Market Revenue Share by Platform, 2022E & 2029F Figure 2: Market Revenue Share by Application, 2022E & 2029F Figure 3: Market Revenue Share by Product, 2022E & 2029F Figure 4: Market Revenue Share by Therapeutic Area, 2022E & 2029F Figure 05: Global Market Value Analysis (US$ Mn), 2012-2021 Figure 06: Global Market Value Forecast (US$ Mn), 2022-2029 Figure 07: Global Market Absolute $ Opportunity, 2022 - 2029 Figure 08: Comparison August 2017 and December 2022, Y-o-Y Forecast Figure 09: Global Market Share Analysis (%), By Platform Type, 2022 & 2029 Figure 10: Global Market Y-o-Y Analysis (%), By Platform Type, 2022-2029 Figure 11: Global Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 12: Global Market Share Analysis (%), By Product, 2022 & 2029 Figure 13: Global Market Y-o-Y Analysis (%), By Product, 2022-2029 Figure 14: Global Market Attractiveness Analysis by Product, 2022-2029 Figure 15: Global Market Share Analysis (%), By Application, 2022 & 2029 Figure 16: Global Market Y-o-Y Analysis (%), By Application, 2022-2029 Figure 17: Global Market Attractiveness Analysis by Application, 2022-2029 Figure 18: Global Market Share Analysis (%), By Therapeutic Area, 2022 & 2029 Figure 19: Global Market Y-o-Y Analysis (%), By Therapeutic Area, 2022-2029 Figure 20: Global Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 21: Global Market Share Analysis (%), By Region, 2022 & 2029 Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2022-2029 Figure 23: Global Market Attractiveness Analysis by Region, 2022-2029 Figure 24: North America Market Value Share by Application (2022E) Figure 25: North America Market Value Share by Platform Type (2022E) Figure 26: North America Market Value Share by Product (2022E) Figure 27: North America Market Value Share by Therapeutic Area (2022E) Figure 28: North America Market Value Share by Country (2022E) Figure 29: North America Market Value Analysis (US$ Mn), 2012-2021 Figure 30: North America Market Value Forecast (US$ Mn), 2022-2029 Figure 31: North America Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 32: North America Market Attractiveness Analysis by Application, 2022-2029 Figure 33: North America Market Attractiveness Analysis by Product, 2022-2029 Figure 34: North America Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 35: North America Market Attractiveness Analysis by Country, 2022-2029 Figure 36: Latin America Market Value Share by Application (2022E) Figure 37: Latin America Market Value Share by Platform Type (2022E) Figure 38: Latin America Market Value Share by Product (2022E) Figure 39: Latin America Market Value Share by Therapeutic Area (2022E) Figure 40: Latin America Market Value Share by Country (2022E) Figure 41: Latin America Market Value Analysis (US$ Mn), 2012-2021 Figure 42: Latin America Market Value Forecast (US$ Mn), 2022-2029 Figure 43: Latin America Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 44: Latin America Market Attractiveness Analysis by Application, 2022-2029 Figure 45: Latin America Market Attractiveness Analysis by Product, 2022-2029 Figure 46: Latin America Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 47: Latin America Market Attractiveness Analysis by Country, 2022-2029 Figure 48: Western Europe Market Value Share by Application (2022E) Figure 49: Western Europe Market Value Share by Platform Type (2022E) Figure 50: Western Europe Market Value Share by Product (2022E) Figure 51: Western Europe Market Value Share by Therapeutic Area (2022E) Figure 52: Western Europe Market Value Share by Country (2022E) Figure 53: Western Europe Market Value Analysis (US$ Mn), 2012-2021 Figure 54: Western Europe Market Value Forecast (US$ Mn), 2022-2029 Figure 55: Western Europe Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 56: Western Europe Market Attractiveness Analysis by Application, 2022-2029 Figure 57: Western Europe Market Attractiveness Analysis by Product, 2022-2029 Figure 58: Western Europe Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 59: Western Europe Market Attractiveness Analysis by Country, 2022-2029 Figure 60: Eastern Europe Market Value Share by Application (2022E) Figure 61: Eastern Europe Market Value Share by Platform Type (2022E) Figure 62: Eastern Europe Market Value Share by Country (2022E) Figure 63: Eastern Europe Market Value Share by Product (2022E) Figure 64: Eastern Europe Market Value Share by Therapeutic Area (2022E) Figure 65: Eastern Europe Market Value Analysis (US$ Mn), 2012-2021 Figure 66: Eastern Europe Market Value Forecast (US$ Mn), 2022-2029 Figure 67: Eastern Europe Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 68: Eastern Europe Market Attractiveness Analysis by Application, 2022-2029 Figure 69: Eastern Europe Market Attractiveness Analysis by Product, 2022-2029 Figure 70: Eastern Europe Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 71: Eastern Europe Market Attractiveness Analysis by Country, 2022-2029 Figure 72: APEJ Market Value Share by Application (2022E) Figure 73: APEJ Market Value Share by Platform Type (2022E) Figure 74: APEJ Market Value Share by Product (2022E) Figure 75: APEJ Market Value Share by Therapeutic Area (2022E) Figure 76: APEJ Market Value Share by Country (2022E) Figure 77: APEJ Market Value Analysis (US$ Mn), 2012-2021 Figure 78: APEJ Market Value Forecast (US$ Mn), 2022-2029 Figure 79: APEJ Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 80: APEJ Market Attractiveness Analysis by Application, 2022-2029 Figure 81: APEJ Market Attractiveness Analysis by Product, 2022-2029 Figure 82: APEJ Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 83: APEJ Market Attractiveness Analysis by Country, 2022-2029 Figure 84: Japan Market Value Share by Application (2022E) Figure 85: Japan Market Value Share by Platform Type (2022E) Figure 86: Japan Market Value Share by Product (2022E) Figure 87: Japan Market Value Share by Therapeutic Area (2022E) Figure 88: Japan Market Value Analysis (US$ Mn), 2012-2021 Figure 89: Japan Market Value Forecast (US$ Mn), 2022-2029 Figure 90: Japan Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 91: Japan Market Attractiveness Analysis by Application, 2022-2029 Figure 92: Japan Market Attractiveness Analysis by Product, 2022-2029 Figure 93: Japan Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 94: Middle East & Africa Market Value Share by Application (2022E) Figure 95: Middle East & Africa Market Value Share by Platform Type (2022E) Figure 96: Middle East & Africa Market Value Share by Product (2022E) Figure 97: Middle East & Africa Market Value Share by Therapeutic Area (2022E) Figure 98: Middle East & Africa Market Value Share by Country (2022E) Figure 99: Middle East & Africa Market Value Analysis (US$ Mn), 2012-2021 Figure 100: Middle East & Africa Market Value Forecast (US$ Mn), 2022-2029 Figure 101: Middle East & Africa Market Attractiveness Analysis by Platform Type, 2022-2029 Figure 102: Middle East & Africa Market Attractiveness Analysis by Application, 2022-2029 Figure 103: Middle East & Africa Market Attractiveness Analysis by Product, 2022-2029 Figure 104: Middle East & Africa Market Attractiveness Analysis by Therapeutic Area, 2022-2029 Figure 105: Middle East & Africa Market Attractiveness Analysis by Country, 2022-2029
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
